A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus

What Was Tested

In this phase 1 trial, researchers set out to test Insulin Glargine.

Side effects and tolerability will be documented.

Blood samples will be taken to assess how the body processes the study drug and the effect of the study drug on blood sugar levels.

It had two arms (groups): LY3209590 (experimental) and Insulin glargine (active comparator).

LY3209590 administered subcutaneously (SC).

Insulin glargine administered SC.

The registry classes the interventions as drug.

Who Took Part

The registry lists 31 actual participants took part.

It was open to people of any sex aged from 18 years up to 70 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have been diagnosed with Type 2 Diabetes Mellitus (T2DM) and treated with basal insulin and up to one non-insulin anti-hyperglycemic medication. Body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²). Native Chinese participant who has both parents and all 4 grandparents of Chinese origin.

The full record lists 5 inclusion and 5 exclusion criteria; among the exclusions: have a diagnosis of type 1 diabetes mellitus or latent autoimmune diabetes; have a history of ketoacidosis or hyperosmolar state/coma episode or severe hypoglycemia or hypoglycemia unawareness in the 6 months prior to screening; are receiving insulin other than once daily basal insulin.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.

The Insulin Glargine group and the comparison group ran side by side rather than switching.

Everyone knew when Insulin Glargine was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2022-11-30 with completion listed for 2023-10-10.

It ran at 1 site in China.

Its stated primary purpose is basic science.

What Was Measured

The main thing measured (primary outcome): Number of Participants with One or More Adverse Events (AEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration (time frame: Baseline up to Week 12). Incidence and Severity of Hypoglycemia (time frame: Baseline up to Week 12).

It also tracked 2 secondary outcomes, for example PD: Change from Baseline in 7-Point Glucose.

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Insulin Glargine in 31 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Insulin Glargine compound page, all human trials.